Product nameAnti-CD79a antibody
See all CD79a primary antibodies
DescriptionRabbit polyclonal to CD79a
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Synthetic peptide corresponding to Human CD79a aa 1-100 conjugated to keyhole limpet haemocyanin.
(Peptide available as
- This antibody gave a positive signal in Human spleen tissue lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 1% BSA, PBS, pH 7.4
Concentration information loading...
PurityImmunogen affinity purified
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab88525 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 20 kDa (predicted molecular weight: 25 kDa).|
FunctionRequired in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. Stimulates SYK autophosphorylation and activation. Binds to BLNK, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK. Also interacts with and increases activity of some Src-family tyrosine kinases. Represses BCR signaling during development of immature B cells.
Involvement in diseaseDefects in CD79A are the cause of agammaglobulinemia type 3 (AGM3) [MIM:613501]. It is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life. Note=Two different mutations, one at the splice donor site of intron 2 and the other at the splice acceptor site for exon 3, have been identified. Both mutations give rise to a truncated protein.
Sequence similaritiesContains 1 Ig-like C2-type (immunoglobulin-like) domain.
Contains 1 ITAM domain.
modificationsPhosphorylated on tyrosine, serine and threonine residues upon B-cell activation. Phosphorylation of tyrosine residues by Src-family kinases is an early and essential feature of the BCR signaling cascade. The phosphorylated tyrosines serve as docking sites for SH2-domain containing kinases, leading to their activation which in turn leads to phosphorylation of downstream targets. Phosphorylation of serine and threonine residues may prevent subsequent tyrosine phosphorylation.
Cellular localizationCell membrane. Following antigen binding, the BCR has been shown to translocate from detergent-soluble regions of the cell membrane to lipid rafts although signal transduction through the complex can also occur outside lipid rafts.
- Information by UniProt
- B lymphocyte-specific MB1 protein antibody
- B-cell antigen receptor complex-associated protein alpha chain antibody
- CD 79a antibody
Anti-CD79a antibody (ab88525) at 1 µg/ml + Human spleen tissue lysate - total protein (ab29699) at 10 µg
Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 25 kDa
Observed band size: 20 kDa why is the actual band size different from the predicted?
Additional bands at: 27 kDa, 49 kDa, 73 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 8 minutes
The band observed at 20 kDa could potentially be a cleaved form of CD79a due to the presence of a 32 amino acid signal peptide.
ab88525 has not yet been referenced specifically in any publications.